TUgether Co., Ltd. – Trademark Portfolio

Entity Type: 03

TUgether Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ZERONATE.

201ho, 2F, 365, Sapyeong-daero, Seocho-gu

Seoul

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ZERONATE
ZERONATE
Registered 2024

Trademark Classifications

TUgether Co., Ltd.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

40
Treatment & Processing (1 filing)

Treatment of materials

Frequently Asked Questions

How many trademarks does TUgether Co., Ltd. have?

TUgether Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does TUgether Co., Ltd. file in?

TUgether Co., Ltd. files trademarks across 3 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 44 (Medical Services), Class 40 (Treatment & Processing). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are TUgether Co., Ltd.'s most well-known trademarks?

TUgether Co., Ltd.'s registered trademark portfolio includes well-known marks such as ZERONATE. These are among 1 currently registered trademark in the portfolio.

What is TUgether Co., Ltd.'s trademark registration success rate?

TUgether Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.